Issue Date: March 13, 2017
FDA warns Wockhardt, Fosun
The U.S. FDA has again warned the Indian generic drug producer Wockhardt about problems at one of its facilities, this time in the U.S. The agency also warned a subsidiary of Fosun Pharmaceutical—one of China’s leading drug producers—regarding a facility in southwest China. In a statement to the National Stock Exchange of India, Wockhardt says FDA has banned its Chicago-based unit, Morton Grove Pharmaceuticals, which produces oral and topical formulations, from launching new products in . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society